Status:
RECRUITING
Comparing the Efficacy of Lyophilized Self Growth Factor Versus PRP Injection for Knee OA
Lead Sponsor:
Tri-Service General Hospital
Conditions:
Knee Osteoarthritis
PRP Injection
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Platelet-rich plasm...
Detailed Description
Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Treatment options i...
Eligibility Criteria
Inclusion
- Male or female, aged over 20 and under 80.
- Consciousness clear and able to communicate.
- Unilateral or bilateral osteoarthritis of the knee with symptoms lasting more than 3 months.
- X-ray imaging shows mild to moderate knee osteoarthritis (Kellgren-Lawrence grades 1-3).
- Knee joint pain with a Visual Analogue Scale (VAS) score greater than 4.
Exclusion
- Severe knee osteoarthritis (Kellgren-Lawrence grade 4).
- Currently systemic infection.
- Received hyaluronic acid or corticosteroid intraarticular injections within the past six months, or received NSAIDs or oral corticosteroid treatment within 7 days prior to treatment.
- The treated joint has undergone joint replacement surgery or major surgery.
- Severe knee deformity or instability.
- Known history of cancers, rheumatoid arthritis, platelet dysfunction, thrombocytopenia, hypofibrinogenemia, acute or chronic infectious diseases, chronic liver disease, or poorly controlled cardiovascular disease or diabetes.
- Currently receiving anticoagulant therapy.
- Long-term or excessive use of aspirin or vitamin E.
- History of HIV/AIDS, syphilis, or other legally notifiable infectious diseases.
- Pregnant or breastfeeding women, or women and men of childbearing potential who are unable to use effective contraception during the treatment period.
- Deemed unsuitable for participation in the trial by the principal investigator.
- Unable to sign the informed consent form.
Key Trial Info
Start Date :
August 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06932614
Start Date
August 1 2025
End Date
July 31 2026
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
No. 325, Sec. 2, Chenggong Rd., Neihu Dist.
Taipei, Taiwan, 114